NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells

Muhammed Akbar Shahid; In Hwa Um; Mustafa Elshani; Ying Zhang; David James Harrison

doi:10.1371/journal.pone.0278209

NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells

Muhammed Akbar Shahid^*, In Hwa Um, Mustafa Elshani, Ying Zhang, David James Harrison

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Acute myeloid leukemia (AML) stem cells are required for the initiation and maintenance of the disease. Activation of the Wnt/β-catenin pathway is required for the survival and development of AML leukaemia stem cells (LSCs) and therefore, targeting β-catenin is a potential therapeutic strategy. NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA) monophosphate, is specifically designed to generate the active anti-cancer metabolite 3’-deoxyadenosine triphosphate (3’-dATP) intracellularly, bypassing key limitations of breakdown, transport, and activation. NUC-7738 is currently in a Phase I/II clinical study for the treatment of patients with advanced solid tumors. Protein expression and immunophenotypic profiling revealed that NUC-7738 caused apoptosis in AML cell lines through reducing PI3K-p110α, phosphorylated Akt (Ser473) and phosphorylated GSK3β (Ser9) resulting in reduced β-catenin, c-Myc and CD44 expression. NUC-7738 reduced β-catenin nuclear expression in AML cells. NUC-7738 also decreased the percentage of CD34⁺ CD38- CD123⁺ (LSC-like cells) from 81% to 47% and reduced the total number and size of leukemic colonies. These results indicate that therapeutic targeting of the PI3K/Akt/GSK3β axis can inhibit β-catenin signalling, resulting in reduced clonogenicity and eventual apoptosis of AML cells.

Original language	English
Article number	e0278209
Number of pages	13
Journal	PLoS ONE
Volume	17
Issue number	12
DOIs	https://doi.org/10.1371/journal.pone.0278209
Publication status	Published - 15 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0278209Licence: CC BY

Revised Manuscript text fileSubmitted manuscript, 42.6 KB
Shahid_2022_PLoS-one_NUC-7738-regulates_CC
Copyright: © 2022 Shahid et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Final published version, 1.83 MBLicence: CC BY

Cite this

@article{7634e32642ec41e3982b6357abc7a286,

title = "NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells",

abstract = "Acute myeloid leukemia (AML) stem cells are required for the initiation and maintenance of the disease. Activation of the Wnt/β-catenin pathway is required for the survival and development of AML leukaemia stem cells (LSCs) and therefore, targeting β-catenin is a potential therapeutic strategy. NUC-7738, a phosphoramidate transformation of 3{\textquoteright}-deoxyadenosine (3{\textquoteright}-dA) monophosphate, is specifically designed to generate the active anti-cancer metabolite 3{\textquoteright}-deoxyadenosine triphosphate (3{\textquoteright}-dATP) intracellularly, bypassing key limitations of breakdown, transport, and activation. NUC-7738 is currently in a Phase I/II clinical study for the treatment of patients with advanced solid tumors. Protein expression and immunophenotypic profiling revealed that NUC-7738 caused apoptosis in AML cell lines through reducing PI3K-p110α, phosphorylated Akt (Ser473) and phosphorylated GSK3β (Ser9) resulting in reduced β-catenin, c-Myc and CD44 expression. NUC-7738 reduced β-catenin nuclear expression in AML cells. NUC-7738 also decreased the percentage of CD34+ CD38- CD123+ (LSC-like cells) from 81% to 47% and reduced the total number and size of leukemic colonies. These results indicate that therapeutic targeting of the PI3K/Akt/GSK3β axis can inhibit β-catenin signalling, resulting in reduced clonogenicity and eventual apoptosis of AML cells.",

author = "Shahid, {Muhammed Akbar} and Um, {In Hwa} and Mustafa Elshani and Ying Zhang and Harrison, {David James}",

note = "Funding: This study was supported by research funding from NuCana plc to all authors.",

year = "2022",

month = dec,

day = "15",

doi = "10.1371/journal.pone.0278209",

language = "English",

volume = "17",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "12",

}

TY - JOUR

T1 - NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells

AU - Shahid, Muhammed Akbar

AU - Um, In Hwa

AU - Elshani, Mustafa

AU - Zhang, Ying

AU - Harrison, David James

N1 - Funding: This study was supported by research funding from NuCana plc to all authors.

PY - 2022/12/15

Y1 - 2022/12/15

N2 - Acute myeloid leukemia (AML) stem cells are required for the initiation and maintenance of the disease. Activation of the Wnt/β-catenin pathway is required for the survival and development of AML leukaemia stem cells (LSCs) and therefore, targeting β-catenin is a potential therapeutic strategy. NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA) monophosphate, is specifically designed to generate the active anti-cancer metabolite 3’-deoxyadenosine triphosphate (3’-dATP) intracellularly, bypassing key limitations of breakdown, transport, and activation. NUC-7738 is currently in a Phase I/II clinical study for the treatment of patients with advanced solid tumors. Protein expression and immunophenotypic profiling revealed that NUC-7738 caused apoptosis in AML cell lines through reducing PI3K-p110α, phosphorylated Akt (Ser473) and phosphorylated GSK3β (Ser9) resulting in reduced β-catenin, c-Myc and CD44 expression. NUC-7738 reduced β-catenin nuclear expression in AML cells. NUC-7738 also decreased the percentage of CD34+ CD38- CD123+ (LSC-like cells) from 81% to 47% and reduced the total number and size of leukemic colonies. These results indicate that therapeutic targeting of the PI3K/Akt/GSK3β axis can inhibit β-catenin signalling, resulting in reduced clonogenicity and eventual apoptosis of AML cells.

AB - Acute myeloid leukemia (AML) stem cells are required for the initiation and maintenance of the disease. Activation of the Wnt/β-catenin pathway is required for the survival and development of AML leukaemia stem cells (LSCs) and therefore, targeting β-catenin is a potential therapeutic strategy. NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA) monophosphate, is specifically designed to generate the active anti-cancer metabolite 3’-deoxyadenosine triphosphate (3’-dATP) intracellularly, bypassing key limitations of breakdown, transport, and activation. NUC-7738 is currently in a Phase I/II clinical study for the treatment of patients with advanced solid tumors. Protein expression and immunophenotypic profiling revealed that NUC-7738 caused apoptosis in AML cell lines through reducing PI3K-p110α, phosphorylated Akt (Ser473) and phosphorylated GSK3β (Ser9) resulting in reduced β-catenin, c-Myc and CD44 expression. NUC-7738 reduced β-catenin nuclear expression in AML cells. NUC-7738 also decreased the percentage of CD34+ CD38- CD123+ (LSC-like cells) from 81% to 47% and reduced the total number and size of leukemic colonies. These results indicate that therapeutic targeting of the PI3K/Akt/GSK3β axis can inhibit β-catenin signalling, resulting in reduced clonogenicity and eventual apoptosis of AML cells.

U2 - 10.1371/journal.pone.0278209

DO - 10.1371/journal.pone.0278209

M3 - Article

SN - 1932-6203

VL - 17

JO - PLoS ONE

JF - PLoS ONE

IS - 12

M1 - e0278209

ER -

NUC-7738 regulates β-catenin signalling resulting in reduced proliferation and self-renewal of AML cells

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this